ArticleHealth services research2022
Prescribing of low- versus high-cost Part B drugs in Medicare Advantage and traditional Medicare.
Article in Health services research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 18 citations in OpenAlex.
- Structural Inequalities in Ambulatory Care: A Scoping Review of Access and Quality and the Neglected Dimension of Patient Safety.International journal of environmental research and public health · 2026Article
- Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028.Journal of managed care & specialty pharmacy · 2026Article
- Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer.Cancer research communications · 2025Article
- Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Potentially Inappropriate Medication Use Among Patients With Dementia in Traditional Medicare and Medicare Advantage.Medical care · 2025Article
- Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare.JAMA health forum · 2025Article
- Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.JAMA network open · 2024Article
- The Promise and Perils of Oncology Care in Medicare Advantage.JAMA network open · 2024Article
- Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.JCO oncology practice · 2024Article
- Increases in Medicare Spending and Use after Private Equity Acquisition of Retina Practices.Ophthalmology · 2024Article
- Is there an advantage? Considerations for researchers studying the effects of the type of Medicare coverage.Health services research · 2024Review
- Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.Journal of managed care & specialty pharmacy · 2024Article
- Biosimilar Uptake in Medicare Advantage vs Traditional Medicare.JAMA health forum · 2023Article
- Role of Patient Sorting in Avoidable Hospital Stays in Medicare Advantage vs Traditional Medicare.JAMA health forum · 2023Article
- Spending on and Use of Clinician-Administered Drugs in Medicare.JAMA health forum · 2023Article
- Article
- Prescribing of low- versus high-cost Part B drugs in Medicare Advantage and traditional Medicare.Health services research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveExamine whether Medicare Advantage (MA) coverage is associated with more efficient prescribing of Part B drugs than traditional Medicare (TM) coverage. DATA SOURCES: Twenty percent sample of 2016 outpatient and carrier TM claims and MA encounter records and Master Beneficiary Summary File data. STUDY
designWe analyzed whether MA enrollees compared to TM enrollees more often received the low-cost Part B drug in four clinical scenarios where multiple similarly effective drugs exist: (1) anti-VEGF agents to treat macular degeneration, (2) bone resorption inhibitors for osteoporosis, (3) bone resorption inhibitors for malignant neoplasms, and (4) intravenous iron for iron deficiency anemia. We then estimated differences in spending if TM prescribing aligned with MA prescribing. Finally, using linear probability models, we examined whether differences in MA and TM prescribing patterns were attributable to differences in the hospitals and clinician practices who treat MA and TM enrollees or differences in how these hospitals and clinician practices treat their MA versus TM patients. DATA COLLECTION/EXTRACTION
methodsNot applicable. PRINCIPAL
findingsIn all cases, a larger share of MA enrollees received the low-cost drug compared to TM enrollees, ranging from 8 percentage points higher for anemia to 16 percentage points higher for macular degeneration in the unadjusted analysis. Results were similar in regression analyses controlling for enrollee characteristics and market factors (5-13 percentage points). If TM prescribing matched MA prescribing, we estimated savings ranging from 6% to 20% of TM spending for each scenario. Differences in prescribing patterns were driven both by MA enrollees receiving treatment at more efficient hospitals and clinician practices and hospitals and clinician practices more often prescribing low-cost drugs to their MA patients.
conclusionsOur findings show MA enrollees were more likely than TM enrollees to receive low-cost Part B drugs in four clinical scenarios where multiple similarly or equally effective treatment options exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.